SCHEMBL2236337

SCHEMBL2236337

Cc1ccc(COc2ccc(Oc3c(C)cc(/C=C/C(=O)N4CCN(Cc5ccc(COc6ccc(Cl)cc6)cc5)CC4)cc3Cl)nc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 8/20 0.50
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MMP1 P03956 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
ADAM17 P78536 1/20 0.43
ACHE P22303 1/20 0.42
HRH3 Q9Y5N1 2/20 0.42
ENPP2 Q13822 1/20 0.41
NAMPT P43490 1/20 0.41
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13582577 1.00 GPR183 (0.50) GPR183MEN1KMT2AMMP1MMP9
SCHEMBL2230876 0.99 GPR183 (0.51) GPR183MEN1KMT2AMMP1MMP9
SCHEMBL2230873 0.99 GPR183 (0.51) GPR183MEN1KMT2AMMP1MMP9
Hydrochloric Acid SCHEMBL2235844 0.98 GPR183 (0.50) GPR183MEN1KMT2AMMP1MMP9
Hydrochloric Acid SCHEMBL2235835 0.98 GPR183 (0.50) GPR183MEN1KMT2AMMP1MMP9
SCHEMBL13582903 0.98 GPR183 (0.49) GPR183MEN1KMT2AMMP1MMP9
SCHEMBL13582900 0.98 GPR183 (0.49) GPR183MEN1KMT2AMMP1MMP9
Hydrochloric Acid SCHEMBL2235031 0.97 GPR183 (0.49) GPR183MEN1KMT2AMMP1MMP9
Hydrochloric Acid SCHEMBL13582928 0.97 GPR183 (0.49) GPR183MEN1KMT2AMMP1MMP9
SCHEMBL2231715 0.97 GPR183 (0.49) GPR183MEN1KMT2AACHEHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 GPR183 1249/4885MEN1 2854/4885KMT2A 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.